The Circulating Fatty Acid Transporter Soluble CD36 Is Not Associated with Carotid Atherosclerosis in Subjects with Type 1 and Type 2 Diabetes Mellitus

This study aimed to determine the association of fatty acid transporter plasma soluble cluster of differentiation 36 (sCD36) with subclinical carotid atherosclerosis (SCA). A cross-sectional study was conducted in 1023 subjects, 225 with type 1 diabetes (T1D), 276 with type 2 diabetes (T2D) and 522...

Full description

Bibliographic Details
Authors: Castelblanco, Esmeralda|||0000-0002-2061-6270, Sanjurjo, Lucía|||0000-0003-4006-8010, Barranco-Altirriba, Maria|||0000-0002-1525-210X, Falguera, Mireia|||0000-0002-7846-8952, Hernández García, Marta|||0000-0003-1237-298X, Soldevila i Madorell, Berta|||0000-0002-4582-4201, Sarrias, Maria-Rosa|||0000-0001-6929-8069, Franch-Nadal, Josep|||0000-0002-5175-1555, Arroyo Díaz, Juan Antonio|||0000-0001-8029-7374, Fernández-Real Lemos, José Manuel|||0000-0002-7442-9323, Alonso Pedrol, Núria|||0000-0001-9687-8050, Mauricio, Didac|||0000-0002-2868-0250
Format: article
Publication Date:2020
Country:España
Institution:Universitat Autònoma de Barcelona
Repository:Dipòsit Digital de Documents de la UAB
Language:English
OAI Identifier:oai:ddd.uab.cat:252645
Online Access:https://ddd.uab.cat/record/252645
https://dx.doi.org/urn:doi:10.3390/jcm9061700
Access Level:Open access
Keyword:Atherosclerotic plaque
Carotid atherosclerosis
Scd36
Type 1 diabetes mellitus
Type 2 diabetes mellitus
Description
Summary:This study aimed to determine the association of fatty acid transporter plasma soluble cluster of differentiation 36 (sCD36) with subclinical carotid atherosclerosis (SCA). A cross-sectional study was conducted in 1023 subjects, 225 with type 1 diabetes (T1D), 276 with type 2 diabetes (T2D) and 522 who were nondiabetic. Carotid atherosclerotic plaque (CAP) presence was determined using B-mode carotid ultrasound imaging. sCD36 were analysed by ELISA, and CD36 surface receptor and mRNA expression were measured by flow cytometry and real-time PCR. Logistic regression models were used to evaluate sCD36 as a biomarker of SCA. Up to 376 (36.75%) participants had at least one CAP, 76 T1D, 164 T2D and 136 without diabetes, while the remaining 647 (63.25%) did not have any CAP. There were no differences in sCD36 between patients with and without CAP in T1D (p = 0.287) or T2D (p = 0.513). Although nondiabetic subjects with plaques had lower sCD36 levels than those without (p = 0.023), the multivariate models revealed no association of sCD36 with CAP in any of the three study groups. No differences were found in surface CD36 or CD36 mRNA expression between the patients with and without CAP. sCD36 is not associated with SCA in type 1 or type 2 diabetic or in nondiabetic subjects.

Similar Items